Atlas Trials

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

Clinical trial NCT05740566 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05740566
Sponsor
Amgen
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Small Cell Lung Cancer (SCLC)
Start date
2023-05-31
Primary completion
2025-01-29
Enrollment
509

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.